CLAIMS

1. Use of a prophylactic and/or therapeutic agent comprising mesenchymal stem cells in the manufacture of a medicament for treating diabetes, wherein the diabetes is caused by an immune checkpoint inhibitor.

2. The use according to claim 1, wherein the diabetes is diabetes caused by an anti-PD-1 antibody or an anti-PD-L1 antibody.

3. The use according to claim 1 or 2, wherein the mesenchymal stem cells are allogeneic to a subject.

4 The use according to any of claims 1 to 3, wherein the mesenchymal stem cells are derived from fat, umbilical cord, or bone marrow.

5. The use according to any of claims 1 to 4, wherein the medicament is comprised in a container carrying a label.